Literature DB >> 19191643

Gram-negative bacteremia upon hospital admission: when should Pseudomonas aeruginosa be suspected?

Vered Schechner1, Vandack Nobre, Keith S Kaye, Moshe Leshno, Michael Giladi, Peter Rohner, Stephan Harbarth, Deverick J Anderson, Adolf W Karchmer, Mitchell J Schwaber, Yehuda Carmeli.   

Abstract

BACKGROUND: Pseudomonas aeruginosa is an uncommon cause of community-acquired bacteremia among patients without severe immunodeficiency. Because tension exists between the need to limit unnecessary use of anti-pseudomonal agents and the need to avoid a delay in appropriate therapy, clinicians require better guidance regarding when to cover empirically for P. aeruginosa. We sought to determine the occurrence of and construct a model to predict P. aeruginosa bacteremia upon hospital admission.
METHODS: A retrospective study was conducted in 4 tertiary care hospitals. Microbiology databases were searched to find all episodes of bacteremia caused by gram-negative rods (GNRs) <or= 48 h after hospital admission. Patient data were extracted from the medical records of 151 patients with P. aeruginosa bacteremia and of 152 randomly selected patients with bacteremia due to Enterobacteriaceae. Discriminative parameters were identified using logistic regression, and the probabilities of having P. aeruginosa bacteremia were calculated.
RESULTS: P. aeruginosa caused 6.8% of 4114 unique patient episodes of GNR bacteremia upon hospital admission (incidence ratio, 5 cases per 10,000 hospital admissions). Independent predictors of P. aeruginosa bacteremia were severe immunodeficiency, age >90 years, receipt of antimicrobial therapy within past 30 days, and presence of a central venous catheter or a urinary device. Among 250 patients without severe immunodeficiency, if no predictor variables existed, the likelihood of having P. aeruginosa bacteremia was 1:42. If >or= 2 predictors existed, the risk increased to nearly 1:3.
CONCLUSIONS: P. aeruginosa bacteremia upon hospital admission in patients without severe immunodeficiency is rare. Among immunocompetent patients with suspected GNR bacteremia who have >or= 2 predictors, empirical anti-pseudomonal treatment is warranted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19191643     DOI: 10.1086/596709

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  24 in total

1.  Impact of healthcare-associated acquisition on community-onset Gram-negative bloodstream infection: a population-based study: healthcare-associated Gram-negative BSI.

Authors:  M N Al-Hasan; J E Eckel-Passow; L M Baddour
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-08       Impact factor: 3.267

2.  Stratification of the impact of inappropriate empirical antimicrobial therapy for Gram-negative bloodstream infections by predicted prognosis.

Authors:  Sarah E Cain; Joseph Kohn; P Brandon Bookstaver; Helmut Albrecht; Majdi N Al-Hasan
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

3.  Community-onset bacteraemia of unknown origin: clinical characteristics, epidemiology and outcome.

Authors:  C Hernandez; N Cobos-Trigueros; C Feher; L Morata; C De La Calle; F Marco; M Almela; A Soriano; J Mensa; A Del Rio; J A Martinez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-08       Impact factor: 3.267

4.  National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases.

Authors:  Dror Marchaim; Tamar Gottesman; Orna Schwartz; Maya Korem; Yasmin Maor; Galia Rahav; Rebekah Karplus; Tsipora Lazarovitch; Eyal Braun; Hana Sprecher; Tamar Lachish; Yonit Wiener-Well; Danny Alon; Michal Chowers; Pnina Ciobotaro; Rita Bardenstein; Alona Paz; Israel Potasman; Michael Giladi; Vered Schechner; Mitchell J Schwaber; Shiri Klarfeld-Lidji; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2010-09-13       Impact factor: 5.191

5.  Duration of hospital admission and the need for empirical antipseudomonal therapy.

Authors:  N Daneman; M Elligsen; S A N Walker; A Simor
Journal:  J Clin Microbiol       Date:  2012-06-06       Impact factor: 5.948

6.  Clinical characteristics, appropriateness of empiric antibiotic therapy, and outcome of Pseudomonas aeruginosa bacteremia across multiple community hospitals.

Authors:  Keith Teelucksingh; Eric Shaw
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-08-30       Impact factor: 3.267

7.  Risk factors for pneumonia due to beta-lactam-susceptible and beta-lactam-resistant Pseudomonas aeruginosa: a case-case-control study.

Authors:  Mohammed J Al-Jaghbeer; Julie Ann Justo; William Owens; Joseph Kohn; P Brandon Bookstaver; Jennifer Hucks; Majdi N Al-Hasan
Journal:  Infection       Date:  2018-05-11       Impact factor: 3.553

8.  Pseudomonas aeruginosa bacteremia secondary to acute right leg cellulitis: case of community-acquired infection.

Authors:  Asrul Abdul Wahab; M M Rahman
Journal:  EXCLI J       Date:  2013-11-29       Impact factor: 4.068

9.  Local audit of empiric antibiotic therapy in bacteremia: A retrospective cohort study.

Authors:  Anthony D Bai; Neal Irfan; Cheryl Main; Philippe El-Helou; Dominik Mertz
Journal:  PLoS One       Date:  2021-03-18       Impact factor: 3.240

10.  Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: a ten-year surveillance study (2000-2009).

Authors:  Inês Linhares; Teresa Raposo; António Rodrigues; Adelaide Almeida
Journal:  BMC Infect Dis       Date:  2013-01-18       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.